ID   TLK2_HUMAN              Reviewed;         772 AA.
AC   Q86UE8; D3DU07; Q9UKI7; Q9Y4F7;
DT   22-AUG-2003, integrated into UniProtKB/Swiss-Prot.
DT   22-AUG-2003, sequence version 2.
DT   12-OCT-2022, entry version 188.
DE   RecName: Full=Serine/threonine-protein kinase tousled-like 2;
DE            EC=2.7.11.1;
DE   AltName: Full=HsHPK;
DE   AltName: Full=PKU-alpha;
DE   AltName: Full=Tousled-like kinase 2;
GN   Name=TLK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), VARIANT ARG-6, FUNCTION,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Placenta {ECO:0000269|PubMed:9427565}, and Testis
RC   {ECO:0000269|PubMed:9427565};
RX   PubMed=9427565; DOI=10.1016/s0378-1119(97)00495-2;
RA   Yamakawa A., Kameoka Y., Hashimoto K., Yoshitake Y., Nishikawa K.,
RA   Tanihara K., Date T.;
RT   "cDNA cloning and chromosomal mapping of genes encoding novel protein
RT   kinases termed PKU-alpha and PKU-beta, which have nuclear localization
RT   signal.";
RL   Gene 202:193-201(1997).
RN   [2] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, MUTAGENESIS OF ASP-613,
RP   SUBCELLULAR LOCATION, INTERACTION WITH TLK1, AND ACTIVITY REGULATION.
RC   TISSUE=Placenta {ECO:0000269|PubMed:10523312};
RX   PubMed=10523312; DOI=10.1093/emboj/18.20.5691;
RA   Sillje H.H.W., Takahashi K., Tanaka K., Van Houwe G., Nigg E.A.;
RT   "Mammalian homologues of the plant tousled gene code for cell-cycle-
RT   regulated kinases with maximal activities linked to ongoing DNA
RT   replication.";
RL   EMBO J. 18:5691-5702(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 189-772 (ISOFORM 2/3), AND TISSUE
RP   SPECIFICITY.
RX   PubMed=9662073; DOI=10.1007/bf02258367;
RA   Huang A.M., Chang T.J., Cho W.L., Chou C.K.;
RT   "From mosquito to man: identification of a novel protein kinase, HsHPK,
RT   which is highly expressed in human hepatoma tissues.";
RL   J. Biomed. Sci. 5:135-140(1998).
RN   [6]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH YWHAZ.
RX   PubMed=10455159; DOI=10.1074/jbc.274.35.24865;
RA   Zhang S., Xing H., Muslin A.J.;
RT   "Nuclear localization of protein kinase U-alpha is regulated by 14-3-3.";
RL   J. Biol. Chem. 274:24865-24872(1999).
RN   [7]
RP   FUNCTION, INTERACTION WITH ASF1A AND ASF1B, AND MUTAGENESIS OF ASP-613.
RX   PubMed=11470414; DOI=10.1016/s0960-9822(01)00298-6;
RA   Sillje H.H.W., Nigg E.A.;
RT   "Identification of human Asf1 chromatin assembly factors as substrates of
RT   Tousled-like kinases.";
RL   Curr. Biol. 11:1068-1073(2001).
RN   [8] {ECO:0000305}
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=12660173; DOI=10.1093/emboj/cdg151;
RA   Groth A., Lukas J., Nigg E.A., Sillje H.H.W., Wernstedt C., Bartek J.,
RA   Hansen K.;
RT   "Human tousled like kinases are targeted by an ATM- and Chk1-dependent DNA
RT   damage checkpoint.";
RL   EMBO J. 22:1676-1687(2003).
RN   [9]
RP   PHOSPHORYLATION AT SER-750, FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=12955071; DOI=10.1038/sj.onc.1206691;
RA   Krause D.R., Jonnalagadda J.C., Gatei M.H., Sillje H.H.W., Zhou B.-B.,
RA   Nigg E.A., Khanna K.;
RT   "Suppression of tousled-like kinase activity after DNA damage or
RT   replication block requires ATM, NBS1 and Chk1.";
RL   Oncogene 22:5927-5937(2003).
RN   [10]
RP   INTERACTION WITH FEZ1 AND FEZ2.
RX   PubMed=16484223; DOI=10.1074/jbc.m513280200;
RA   Assmann E.M., Alborghetti M.R., Camargo M.E.R., Kobarg J.;
RT   "FEZ1 dimerization and interaction with transcription regulatory proteins
RT   involves its coiled-coil region.";
RL   J. Biol. Chem. 281:9869-9881(2006).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-99, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-94 AND SER-134, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [15]
RP   FUNCTION AS ASF1A AND ASF1B KINASE, AND ACTIVITY REGULATION.
RX   PubMed=20016786; DOI=10.1371/journal.pone.0008328;
RA   Pilyugin M., Demmers J., Verrijzer C.P., Karch F., Moshkin Y.M.;
RT   "Phosphorylation-mediated control of histone chaperone ASF1 levels by
RT   Tousled-like kinases.";
RL   PLoS ONE 4:E8328-E8328(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-99, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [19]
RP   FUNCTION.
RX   PubMed=22354037; DOI=10.1038/emboj.2012.36;
RA   McKnight N.C., Jefferies H.B., Alemu E.A., Saunders R.E., Howell M.,
RA   Johansen T., Tooze S.A.;
RT   "Genome-wide siRNA screen reveals amino acid starvation-induced autophagy
RT   requires SCOC and WAC.";
RL   EMBO J. 31:1931-1946(2012).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-73; SER-94; SER-99; SER-115;
RP   SER-117 AND SER-134, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [22]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-6; ASP-54; GLY-95; GLY-108; LEU-109;
RP   LEU-173 AND GLN-262.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [23]
RP   VARIANT MRD57 720-ARG--ASN-772 DEL, AND INVOLVEMENT IN MRD57.
RX   PubMed=27479843; DOI=10.1038/nn.4352;
RA   Lelieveld S.H., Reijnders M.R., Pfundt R., Yntema H.G., Kamsteeg E.J.,
RA   de Vries P., de Vries B.B., Willemsen M.H., Kleefstra T., Loehner K.,
RA   Vreeburg M., Stevens S.J., van der Burgt I., Bongers E.M., Stegmann A.P.,
RA   Rump P., Rinne T., Nelen M.R., Veltman J.A., Vissers L.E., Brunner H.G.,
RA   Gilissen C.;
RT   "Meta-analysis of 2,104 trios provides support for 10 new genes for
RT   intellectual disability.";
RL   Nat. Neurosci. 19:1194-1196(2016).
RN   [24]
RP   VARIANTS MRD57 13-GLN--ASN-772 DEL; 61-ARG--ASN-772 DEL; 68-GLU--ASN-772
RP   DEL; 259-TYR--ASN-772 DEL; 262-ARG--ASN-772 DEL; ASP-297; 303-ARG--ASN-772
RP   DEL; 330-SER--ASN-772 DEL; GLN-339; TRP-339; LYS-447; ARG-493; ARG-518;
RP   TRP-568; 573-GLN--ASN-772 DEL; ASN-629; ARG-680; 720-ARG--ASN-772 DEL AND
RP   746-ARG--ASN-772 DEL, AND INVOLVEMENT IN MRD57.
RX   PubMed=29861108; DOI=10.1016/j.ajhg.2018.04.014;
RG   Deciphering Developmental Disorders Study;
RA   Reijnders M.R.F., Miller K.A., Alvi M., Goos J.A.C., Lees M.M.,
RA   de Burca A., Henderson A., Kraus A., Mikat B., de Vries B.B.A., Isidor B.,
RA   Kerr B., Marcelis C., Schluth-Bolard C., Deshpande C., Ruivenkamp C.A.L.,
RA   Wieczorek D., Baralle D., Blair E.M., Engels H., Luedecke H.J., Eason J.,
RA   Santen G.W.E., Clayton-Smith J., Chandler K., Tatton-Brown K., Payne K.,
RA   Helbig K., Radtke K., Nugent K.M., Cremer K., Strom T.M., Bird L.M.,
RA   Sinnema M., Bitner-Glindzicz M., van Dooren M.F., Alders M., Koopmans M.,
RA   Brick L., Kozenko M., Harline M.L., Klaassens M., Steinraths M.,
RA   Cooper N.S., Edery P., Yap P., Terhal P.A., van der Spek P.J., Lakeman P.,
RA   Taylor R.L., Littlejohn R.O., Pfundt R., Mercimek-Andrews S.,
RA   Stegmann A.P.A., Kant S.G., McLean S., Joss S., Swagemakers S.M.A.,
RA   Douzgou S., Wall S.A., Kuery S., Calpena E., Koelling N., McGowan S.J.,
RA   Twigg S.R.F., Mathijssen I.M.J., Nellaker C., Brunner H.G., Wilkie A.O.M.;
RT   "De Novo and Inherited Loss-of-Function Variants in TLK2: Clinical and
RT   Genotype-Phenotype Evaluation of a Distinct Neurodevelopmental Disorder.";
RL   Am. J. Hum. Genet. 102:1195-1203(2018).
CC   -!- FUNCTION: Serine/threonine-protein kinase involved in the process of
CC       chromatin assembly and probably also DNA replication, transcription,
CC       repair, and chromosome segregation. Phosphorylates the chromatin
CC       assembly factors ASF1A and ASF1B. Phosphorylation of ASF1A prevents its
CC       proteasome-mediated degradation, thereby enhancing chromatin assembly.
CC       Negative regulator of amino acid starvation-induced autophagy.
CC       {ECO:0000269|PubMed:10523312, ECO:0000269|PubMed:11470414,
CC       ECO:0000269|PubMed:12660173, ECO:0000269|PubMed:12955071,
CC       ECO:0000269|PubMed:20016786, ECO:0000269|PubMed:22354037,
CC       ECO:0000269|PubMed:9427565}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:10523312, ECO:0000269|PubMed:12660173,
CC         ECO:0000269|PubMed:9427565};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:10523312,
CC         ECO:0000269|PubMed:12660173, ECO:0000269|PubMed:9427565};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:10523312, ECO:0000269|PubMed:12660173,
CC         ECO:0000269|PubMed:9427565};
CC   -!- ACTIVITY REGULATION: Cell cycle-regulated, with maximal activity in the
CC       S-phase. Rapidly and transiently inhibited by phosphorylation following
CC       the generation of DNA double-stranded breaks during S-phase, probably
CC       by CHEK1, possibly at Ser-750. This inhibition is cell cycle
CC       checkpoint- and ATM-dependent. {ECO:0000269|PubMed:10523312,
CC       ECO:0000269|PubMed:12660173, ECO:0000269|PubMed:12955071,
CC       ECO:0000269|PubMed:20016786}.
CC   -!- SUBUNIT: Monomer and heterodimer with TLK1. Interacts with ASF1A and
CC       ASF1B. Association with 14-3-3 proteins such as YWHAZ regulates
CC       subcellular location. May also interact with FEZ1/LZTS1 and FEZ2.
CC       {ECO:0000269|PubMed:10455159, ECO:0000269|PubMed:10523312,
CC       ECO:0000269|PubMed:11470414, ECO:0000269|PubMed:16484223}.
CC   -!- INTERACTION:
CC       Q86UE8; Q8NHQ1: CEP70; NbExp=3; IntAct=EBI-1047967, EBI-739624;
CC       Q86UE8; Q9NPF5: DMAP1; NbExp=3; IntAct=EBI-1047967, EBI-399105;
CC       Q86UE8; Q96NE9-2: FRMD6; NbExp=3; IntAct=EBI-1047967, EBI-13213391;
CC       Q86UE8; Q96IK5: GMCL1; NbExp=3; IntAct=EBI-1047967, EBI-2548508;
CC       Q86UE8; Q15306: IRF4; NbExp=2; IntAct=EBI-1047967, EBI-751345;
CC       Q86UE8; Q92985: IRF7; NbExp=2; IntAct=EBI-1047967, EBI-968267;
CC       Q86UE8; Q02548: PAX5; NbExp=3; IntAct=EBI-1047967, EBI-296331;
CC       Q86UE8; P26367: PAX6; NbExp=3; IntAct=EBI-1047967, EBI-747278;
CC       Q86UE8; Q86UE8: TLK2; NbExp=3; IntAct=EBI-1047967, EBI-1047967;
CC       Q86UE8; Q7KZS0: UBE2I; NbExp=3; IntAct=EBI-1047967, EBI-10180829;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm, perinuclear region.
CC       Cytoplasm, cytoskeleton. Note=Colocalizes with the cytoplasmic
CC       intermediate filament system during the G1 phase of the cell cycle.
CC       Present in the perinuclear region at S phase and in the nucleus at late
CC       G2.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1 {ECO:0000305};
CC         IsoId=Q86UE8-1; Sequence=Displayed;
CC       Name=2 {ECO:0000269|PubMed:10523312};
CC         IsoId=Q86UE8-2; Sequence=VSP_050573;
CC       Name=3 {ECO:0000269|PubMed:9427565};
CC         IsoId=Q86UE8-3; Sequence=VSP_050572, VSP_050573;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Detected in placenta, fetal liver,
CC       kidney, pancreas, heart and skeletal muscle. Highly expressed in
CC       testis. Detected in spleen, thymus, colon, ovary, small intestine,
CC       prostate and peripheral blood leukocytes. {ECO:0000269|PubMed:9427565,
CC       ECO:0000269|PubMed:9662073}.
CC   -!- PTM: Phosphorylated at Ser-750, probably by CHEK1.
CC       {ECO:0000269|PubMed:12955071}.
CC   -!- DISEASE: Intellectual developmental disorder, autosomal dominant 57
CC       (MRD57) [MIM:618050]: A disorder characterized by significantly below
CC       average general intellectual functioning associated with impairments in
CC       adaptive behavior and manifested during the developmental period. MRD57
CC       is characterized by delayed psychomotor development apparent in infancy
CC       or early childhood, and a variety of behavioral abnormalities. Affected
CC       individuals may have severe gastro-intestinal problems, and facial
CC       dysmorphism. {ECO:0000269|PubMed:27479843,
CC       ECO:0000269|PubMed:29861108}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC       kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF03095.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAH44925.2; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAA20561.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB004884; BAA20561.1; ALT_INIT; mRNA.
DR   EMBL; AF162667; AAF03095.1; ALT_INIT; mRNA.
DR   EMBL; CH471109; EAW94346.1; -; Genomic_DNA.
DR   EMBL; CH471109; EAW94348.1; -; Genomic_DNA.
DR   EMBL; BC044925; AAH44925.2; ALT_INIT; mRNA.
DR   CCDS; CCDS11633.1; -. [Q86UE8-2]
DR   CCDS; CCDS45753.1; -. [Q86UE8-3]
DR   CCDS; CCDS62283.1; -. [Q86UE8-1]
DR   RefSeq; NP_001271262.1; NM_001284333.1. [Q86UE8-1]
DR   RefSeq; NP_001271292.1; NM_001284363.1. [Q86UE8-3]
DR   RefSeq; NP_006843.2; NM_006852.3. [Q86UE8-2]
DR   RefSeq; XP_011522518.1; XM_011524216.2. [Q86UE8-1]
DR   RefSeq; XP_011522519.1; XM_011524217.2. [Q86UE8-1]
DR   RefSeq; XP_011522524.1; XM_011524222.2. [Q86UE8-1]
DR   RefSeq; XP_016879533.1; XM_017024044.1. [Q86UE8-2]
DR   RefSeq; XP_016879535.1; XM_017024046.1.
DR   RefSeq; XP_016879536.1; XM_017024047.1.
DR   RefSeq; XP_016879540.1; XM_017024051.1. [Q86UE8-3]
DR   RefSeq; XP_016879541.1; XM_017024052.1.
DR   RefSeq; XP_016879542.1; XM_017024053.1. [Q86UE8-3]
DR   PDB; 5O0Y; X-ray; 2.86 A; A=191-755.
DR   PDB; 7LO0; X-ray; 2.71 A; I/J/K/L/M/N/O/P/Q/R/T/U/V/W/X/Y=3-23.
DR   PDBsum; 5O0Y; -.
DR   PDBsum; 7LO0; -.
DR   AlphaFoldDB; Q86UE8; -.
DR   SMR; Q86UE8; -.
DR   BioGRID; 116201; 86.
DR   IntAct; Q86UE8; 32.
DR   MINT; Q86UE8; -.
DR   STRING; 9606.ENSP00000316512; -.
DR   BindingDB; Q86UE8; -.
DR   ChEMBL; CHEMBL5404; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q86UE8; -.
DR   iPTMnet; Q86UE8; -.
DR   PhosphoSitePlus; Q86UE8; -.
DR   BioMuta; TLK2; -.
DR   DMDM; 34222826; -.
DR   EPD; Q86UE8; -.
DR   jPOST; Q86UE8; -.
DR   MassIVE; Q86UE8; -.
DR   MaxQB; Q86UE8; -.
DR   PaxDb; Q86UE8; -.
DR   PeptideAtlas; Q86UE8; -.
DR   PRIDE; Q86UE8; -.
DR   ProteomicsDB; 69811; -. [Q86UE8-1]
DR   ProteomicsDB; 69812; -. [Q86UE8-2]
DR   ProteomicsDB; 69813; -. [Q86UE8-3]
DR   Antibodypedia; 31236; 372 antibodies from 30 providers.
DR   DNASU; 11011; -.
DR   Ensembl; ENST00000326270.13; ENSP00000316512.9; ENSG00000146872.19. [Q86UE8-1]
DR   Ensembl; ENST00000343388.11; ENSP00000340800.7; ENSG00000146872.19. [Q86UE8-3]
DR   Ensembl; ENST00000346027.10; ENSP00000275780.7; ENSG00000146872.19. [Q86UE8-2]
DR   Ensembl; ENST00000682085.1; ENSP00000506744.1; ENSG00000146872.19. [Q86UE8-2]
DR   Ensembl; ENST00000683104.1; ENSP00000508242.1; ENSG00000146872.19. [Q86UE8-3]
DR   GeneID; 11011; -.
DR   KEGG; hsa:11011; -.
DR   MANE-Select; ENST00000346027.10; ENSP00000275780.7; NM_006852.6; NP_006843.2. [Q86UE8-2]
DR   UCSC; uc002izz.5; human. [Q86UE8-1]
DR   CTD; 11011; -.
DR   DisGeNET; 11011; -.
DR   GeneCards; TLK2; -.
DR   HGNC; HGNC:11842; TLK2.
DR   HPA; ENSG00000146872; Low tissue specificity.
DR   MalaCards; TLK2; -.
DR   MIM; 608439; gene.
DR   MIM; 618050; phenotype.
DR   neXtProt; NX_Q86UE8; -.
DR   OpenTargets; ENSG00000146872; -.
DR   PharmGKB; PA36544; -.
DR   VEuPathDB; HostDB:ENSG00000146872; -.
DR   eggNOG; KOG1151; Eukaryota.
DR   GeneTree; ENSGT00950000182984; -.
DR   InParanoid; Q86UE8; -.
DR   OMA; FETQASS; -.
DR   OrthoDB; 693214at2759; -.
DR   PhylomeDB; Q86UE8; -.
DR   TreeFam; TF315233; -.
DR   PathwayCommons; Q86UE8; -.
DR   SignaLink; Q86UE8; -.
DR   SIGNOR; Q86UE8; -.
DR   BioGRID-ORCS; 11011; 238 hits in 1077 CRISPR screens.
DR   ChiTaRS; TLK2; human.
DR   GeneWiki; TLK2; -.
DR   GenomeRNAi; 11011; -.
DR   Pharos; Q86UE8; Tchem.
DR   PRO; PR:Q86UE8; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q86UE8; protein.
DR   Bgee; ENSG00000146872; Expressed in calcaneal tendon and 113 other tissues.
DR   ExpressionAtlas; Q86UE8; baseline and differential.
DR   Genevisible; Q86UE8; HS.
DR   GO; GO:0005882; C:intermediate filament; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0071480; P:cellular response to gamma radiation; IDA:UniProtKB.
DR   GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW.
DR   GO; GO:0007059; P:chromosome segregation; IMP:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0051179; P:localization; EXP:DisProt.
DR   GO; GO:0010507; P:negative regulation of autophagy; NAS:BHF-UCL.
DR   GO; GO:0032435; P:negative regulation of proteasomal ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:1902275; P:regulation of chromatin organization; IDA:UniProtKB.
DR   DisProt; DP02475; -.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR027086; TLK2.
DR   PANTHER; PTHR22974:SF20; PTHR22974:SF20; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell cycle;
KW   Chromatin regulator; Coiled coil; Cytoplasm; Cytoskeleton; Disease variant;
KW   DNA damage; Intellectual disability; Kinase; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase.
FT   CHAIN           1..772
FT                   /note="Serine/threonine-protein kinase tousled-like 2"
FT                   /id="PRO_0000086754"
FT   DOMAIN          462..741
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          24..126
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          180..208
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          342..385
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          225..276
FT                   /evidence="ECO:0000255"
FT   COILED          317..347
FT                   /evidence="ECO:0000255"
FT   COILED          403..451
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        27..45
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        48..71
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        104..120
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        355..383
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        592
FT                   /note="Proton acceptor"
FT   BINDING         468..476
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         491
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         73
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         94
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         99
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         115
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         117
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         134
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         750
FT                   /note="Phosphoserine; by CHEK1"
FT                   /evidence="ECO:0000305|PubMed:12955071"
FT   VAR_SEQ         90..121
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:9427565"
FT                   /id="VSP_050572"
FT   VAR_SEQ         375..396
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:10523312,
FT                   ECO:0000303|PubMed:9427565"
FT                   /id="VSP_050573"
FT   VARIANT         6
FT                   /note="H -> R (in dbSNP:rs45550140)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:9427565"
FT                   /id="VAR_041216"
FT   VARIANT         13..772
FT                   /note="Missing (in MRD57)"
FT                   /evidence="ECO:0000269|PubMed:29861108"
FT                   /id="VAR_081017"
FT   VARIANT         54
FT                   /note="E -> D"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041217"
FT   VARIANT         61..772
FT                   /note="Missing (in MRD57)"
FT                   /evidence="ECO:0000269|PubMed:29861108"
FT                   /id="VAR_081018"
FT   VARIANT         68..772
FT                   /note="Missing (in MRD57)"
FT                   /evidence="ECO:0000269|PubMed:29861108"
FT                   /id="VAR_081019"
FT   VARIANT         95
FT                   /note="A -> G (in dbSNP:rs2598147)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041218"
FT   VARIANT         108
FT                   /note="A -> G"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041219"
FT   VARIANT         109
FT                   /note="R -> L (in dbSNP:rs1555617262)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041220"
FT   VARIANT         173
FT                   /note="F -> L (in a gastric adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs1331331651)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041221"
FT   VARIANT         259..772
FT                   /note="Missing (in MRD57)"
FT                   /evidence="ECO:0000269|PubMed:29861108"
FT                   /id="VAR_081020"
FT   VARIANT         262..772
FT                   /note="Missing (in MRD57)"
FT                   /evidence="ECO:0000269|PubMed:29861108"
FT                   /id="VAR_081021"
FT   VARIANT         262
FT                   /note="R -> Q (in dbSNP:rs762409144)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041222"
FT   VARIANT         297
FT                   /note="G -> D (in MRD57; unknown pathological significance;
FT                   dbSNP:rs1555639254)"
FT                   /evidence="ECO:0000269|PubMed:29861108"
FT                   /id="VAR_081022"
FT   VARIANT         303..772
FT                   /note="Missing (in MRD57)"
FT                   /evidence="ECO:0000269|PubMed:29861108"
FT                   /id="VAR_081023"
FT   VARIANT         330..772
FT                   /note="Missing (in MRD57)"
FT                   /evidence="ECO:0000269|PubMed:29861108"
FT                   /id="VAR_081024"
FT   VARIANT         339
FT                   /note="R -> Q (in MRD57; unknown pathological significance;
FT                   dbSNP:rs1567948287)"
FT                   /evidence="ECO:0000269|PubMed:29861108"
FT                   /id="VAR_081025"
FT   VARIANT         339
FT                   /note="R -> W (in MRD57; unknown pathological significance;
FT                   dbSNP:rs1567948262)"
FT                   /evidence="ECO:0000269|PubMed:29861108"
FT                   /id="VAR_081026"
FT   VARIANT         447
FT                   /note="E -> K (in MRD57; unknown pathological significance;
FT                   dbSNP:rs1567959483)"
FT                   /evidence="ECO:0000269|PubMed:29861108"
FT                   /id="VAR_081027"
FT   VARIANT         493
FT                   /note="H -> R (in MRD57; dbSNP:rs1567974030)"
FT                   /evidence="ECO:0000269|PubMed:29861108"
FT                   /id="VAR_081028"
FT   VARIANT         518
FT                   /note="H -> R (in MRD57; dbSNP:rs1567995650)"
FT                   /evidence="ECO:0000269|PubMed:29861108"
FT                   /id="VAR_081029"
FT   VARIANT         568
FT                   /note="R -> W (in MRD57; dbSNP:rs1283838287)"
FT                   /evidence="ECO:0000269|PubMed:29861108"
FT                   /id="VAR_081030"
FT   VARIANT         573..772
FT                   /note="Missing (in MRD57)"
FT                   /evidence="ECO:0000269|PubMed:29861108"
FT                   /id="VAR_081031"
FT   VARIANT         629
FT                   /note="D -> N (in MRD57; dbSNP:rs1568006217)"
FT                   /evidence="ECO:0000269|PubMed:29861108"
FT                   /id="VAR_081032"
FT   VARIANT         680
FT                   /note="P -> R (in MRD57; dbSNP:rs1568018905)"
FT                   /evidence="ECO:0000269|PubMed:29861108"
FT                   /id="VAR_081033"
FT   VARIANT         720..772
FT                   /note="Missing (in MRD57; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:27479843,
FT                   ECO:0000269|PubMed:29861108"
FT                   /id="VAR_081034"
FT   VARIANT         746..772
FT                   /note="Missing (in MRD57; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:29861108"
FT                   /id="VAR_081035"
FT   MUTAGEN         613
FT                   /note="D->A: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:10523312,
FT                   ECO:0000269|PubMed:11470414"
FT   CONFLICT        1
FT                   /note="M -> I (in Ref. 1; BAA20561)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        161
FT                   /note="T -> P (in Ref. 1; BAA20561)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        207
FT                   /note="Q -> R (in Ref. 2; AAF03095)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        562
FT                   /note="M -> I (in Ref. 1; BAA20561)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        727
FT                   /note="E -> R (in Ref. 2; AAF03095)"
FT                   /evidence="ECO:0000305"
FT   HELIX           10..21
FT                   /evidence="ECO:0007829|PDB:7LO0"
FT   STRAND          463..470
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   STRAND          472..481
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   TURN            482..485
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   STRAND          486..494
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   STRAND          497..499
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   HELIX           502..519
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   STRAND          529..534
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   STRAND          539..545
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   STRAND          549..551
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   HELIX           552..559
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   HELIX           564..581
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   STRAND          584..586
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   HELIX           595..597
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   STRAND          598..600
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   STRAND          603..607
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   STRAND          609..611
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   TURN            622..624
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   TURN            627..629
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   HELIX           641..643
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   HELIX           646..649
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   STRAND          652..654
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   HELIX           661..676
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   STRAND          680..682
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   HELIX           687..693
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   TURN            694..698
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   STRAND          706..708
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   HELIX           712..721
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   HELIX           726..728
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   HELIX           732..735
FT                   /evidence="ECO:0007829|PDB:5O0Y"
FT   HELIX           739..741
FT                   /evidence="ECO:0007829|PDB:5O0Y"
SQ   SEQUENCE   772 AA;  87661 MW;  765EE37ED4A4ADEC CRC64;
     MMEELHSLDP RRQELLEARF TGVGVSKGPL NSESSNQSLC SVGSLSDKEV ETPEKKQNDQ
     RNRKRKAEPY ETSQGKGTPR GHKISDYFEF AGGSAPGTSP GRSVPPVARS SPQHSLSNPL
     PRRVEQPLYG LDGSAAKEAT EEQSALPTLM SVMLAKPRLD TEQLAQRGAG LCFTFVSAQQ
     NSPSSTGSGN TEHSCSSQKQ ISIQHRQTQS DLTIEKISAL ENSKNSDLEK KEGRIDDLLR
     ANCDLRRQID EQQKMLEKYK ERLNRCVTMS KKLLIEKSKQ EKMACRDKSM QDRLRLGHFT
     TVRHGASFTE QWTDGYAFQN LIKQQERINS QREEIERQRK MLAKRKPPAM GQAPPATNEQ
     KQRKSKTNGA ENETPSSGNT ELKDTAPALG AHSLLRLTLA EYHEQEEIFK LRLGHLKKEE
     AEIQAELERL ERVRNLHIRE LKRIHNEDNS QFKDHPTLND RYLLLHLLGR GGFSEVYKAF
     DLTEQRYVAV KIHQLNKNWR DEKKENYHKH ACREYRIHKE LDHPRIVKLY DYFSLDTDSF
     CTVLEYCEGN DLDFYLKQHK LMSEKEARSI IMQIVNALKY LNEIKPPIIH YDLKPGNILL
     VNGTACGEIK ITDFGLSKIM DDDSYNSVDG MELTSQGAGT YWYLPPECFV VGKEPPKISN
     KVDVWSVGVI FYQCLYGRKP FGHNQSQQDI LQENTILKAT EVQFPPKPVV TPEAKAFIRR
     CLAYRKEDRI DVQQLACDPY LLPHIRKSVS TSSPAGAAIA STSGASNNSS SN
//
